Journal Article
. 2013 Apr;19(3).
doi: 10.1111/tbj.12099.

Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation

Julianne R Biroschak 1 Gordon F Schwartz  Juan P Palazzo  Adam D Toll  Kristin L Brill  Rebecca J Jaslow  Sun Yong Lee  
  • PMID: 23614365
  •     8 citations


Oncotype DX, a gene-expression profiling assay, provides stratification of patients with estrogen-receptor positive, lymph-node-negative early breast cancer into risk groups based on recurrence score, which are associated with distant recurrence and response to chemotherapy. This study aims to determine whether Oncotype DX influences clinicians' treatment decisions, and whether assay results correlate with histologic assessment. Fifty patients with estrogen-receptor positive, node-negative early breast cancer analyzed by Oncotype DX and operated on by two breast surgeons were included. To assess effect on treatment decisions, clinical vignettes were created by retrospective chart review. Physicians were then presented with the clinical vignettes and instructed to make a treatment decisions (i.e., hormone therapy alone versus hormone therapy combined with chemotherapy) both before and after knowledge of the recurrence score. To assess correlation with histologic assessment, a prospective, blinded review of tumor slides was performed by two pathologists. Based on this review, tumors were placed into low, intermediate and high risk groups for comparison with Oncotype DX assay results. Treatment decisions were changed based on Oncotype DX results in 36 and 18% of cases by breast surgeons and medical oncologists, respectively. All tumors categorized as high risk by Oncotype DX were categorized as high risk based on histologic assessment, and 96% of cases categorized as low risk by recurrence score were categorized as low or intermediate risk by histologic assessment. Oncotype DX significantly influences management of estrogen-receptor positive, lymph-node-negative early breast cancer. Further studies are needed to assess association of histologic categorization to assay results.

The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea.
Moo Hyun Lee, Wonshik Han, +7 authors, Eun Sook Lee.
Cancer Res Treat, 2014 Nov 11; 47(2). PMID: 25381828    Free PMC article.
Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
Bradley M Turner, Kristin A Skinner, +6 authors, David G Hicks.
Mod Pathol, 2015 May 02; 28(7). PMID: 25932962
Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Megan C Roberts, Morris Weinberger, +5 authors, Stephanie B Wheeler.
J Clin Oncol, 2015 Nov 26; 34(2). PMID: 26598755    Free PMC article.
Implementation of the 21-gene recurrence score test in the United States in 2011.
Julie A Lynch, Brygida Berse, +5 authors, Andrew N Freedman.
Genet Med, 2016 Feb 19; 18(10). PMID: 26890451
How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment.
Deborah A Marshall, Ken Deal, +3 authors, Maureen Trudeau.
BMJ Open, 2016 Jun 04; 6(6). PMID: 27256091    Free PMC article.
21-Gene recurrence score testing among Medicare beneficiaries with breast cancer in 2010-2013.
Julie A Lynch, Brygida Berse, Nicole Coomer, John Kautter.
Genet Med, 2017 Mar 24; 19(10). PMID: 28333918
Apparent diffusion coefficient in estrogen receptor-positive and lymph node-negative invasive breast cancers at 3.0T DW-MRI: A potential predictor for an oncotype Dx test recurrence score.
Sunitha B Thakur, Manuela Durando, +5 authors, Elizabeth A Morris.
J Magn Reson Imaging, 2017 Jun 24; 47(2). PMID: 28640531    Free PMC article.
Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26.
Bradley M Turner, Mary Ann Gimenez-Sanders, +6 authors, David G Hicks.
Cancer Med, 2019 Jun 15; 8(9). PMID: 31199586    Free PMC article.